September 11, 2024 — The FDA has launched an investigation of the potential exposure to heavy [...]
Much less money is flowing into the sector as venture investors focus on technologies with less [...]
Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. [...]
Still, in an editorial that accompanied two JAMA studies, experts urged “continued vigilance” to ensure GLP-1 [...]
The decision to turn down an application from Lykos Therapeutics comes at a pivotal time for [...]
August 13, 2024 | In today's data-driven world, clinical trials rely heavily on effective data management to [...]
TOPLINE: A novel method combining genetic variants, symptoms, and patient characteristics is moderately successful at predicting [...]
Adaptimmune’s Tecelra is the first TCR cell therapy to reach the U.S. market, but arrives with [...]
Head and neck cancer is currently recognised as the sixth most common cancer globally Researchers from [...]
Strapped for cash and searching for new profits, Tennessee-based Erlanger Health System illegally paid excessive salaries [...]
